1. Signaling Pathways
  2. GPCR/G Protein
  3. GCGR

GCGR

Glucagon Receptor

GCGR (glucagon receptor) is in the G protein-coupled receptor family, that is important in controlling blood glucose levels. The glucagon receptor is a 62 kDa protein that is activated by glucagon and is a member of the class B G-protein coupled family of receptors, coupled to G alpha i, Gs and to a lesser extent G alpha q. Stimulation of the receptor results in activation of adenylate cyclase and increased levels of intracellular cAMP. In humans, the glucagon receptor is encoded by the GCGR gene. Glucagon receptors are mainly expressed in liver and in kidney with lesser amounts found in heart, adipose tissue, spleen, thymus, adrenal glands, pancreas, cerebral cortex, and gastrointestinal tract.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-114118
    Semaglutide
    Agonist 99.84%
    Semaglutide, a long-acting GLP-1 analogue, is a glucagon-like peptide-1 (GLP-1) receptor agonist. Semaglutide has the potential for type 2 diabetes treatment.
    Semaglutide
  • HY-13443
    Exendin-4
    Agonist 99.94%
    Exendin-4 (Exenatide), a 39 amino acid peptide, is a long-acting glucagon-like peptide-1 receptor agonist with an IC50 of 3.22 nM.
    Exendin-4
  • HY-P0014
    Liraglutide
    Agonist 99.85%
    Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used clinically to treat type 2 diabetes mellitus.
    Liraglutide
  • HY-P0082
    Glucagon (1-29), bovine, human
    99.84%
    Glucagon (1-29), bovine, human, porcine is a peptide hormone, produced by pancreatic α-cells. Glucagon stimulates gluconeogenesis. Glucagon (1-29), bovine, human, porcine activates HNF4α and increases HNF4α phosphorylation.
    Glucagon (1-29), bovine, human
  • HY-P3506
    Retatrutide
    Agonist 99.95%
    Retatrutide (LY3437943) is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide binds human GCGR, GIPR, and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide can be used for the research of obesity.
    Retatrutide
  • HY-114118F
    Semaglutide, FITC labeled
    Agonist
    Semaglutide, FITC labeled is a FITC labeled Semaglutide. Semaglutide, a long-acting GLP-1 alogue, is a glucagon-like peptide-1 (GLP-1) receptor agonist. Semaglutide has the potential for type 2 diabetes treatment.
    Semaglutide, FITC labeled
  • HY-116854
    NNC 92-1687
    Antagonist 98.74%
    NNC 92-1687 is a non-peptide competitive human glucagon receptor antagonist (IC50=20 μM; Ki=9.1 μM). NNC 92-1687 can be used in the research of type 2 diabetes.
    NNC 92-1687
  • HY-114118B
    Semaglutide acetate
    Agonist 99.59%
    Semaglutide acetate, a long-acting GLP-1 analogue, is a glucagon-like peptide-1 (GLP-1) receptor agonist. Semaglutide acetate has the potential for type 2 diabetes treatment.
    Semaglutide acetate
  • HY-P0055
    GLP-1(7-37)
    99.82%
    GLP-1(7-37) is an intestinal insulinotropic hormone that augments glucose induced insulin secretion.
    GLP-1(7-37)
  • HY-112185
    Orforglipron
    Agonist 99.80%
    Orforglipron (LY3502970) (Compound 67) is an orally active agonist for Glucagon-like peptide-1 receptor (GLP-1R), which exhibits potency in ameliorates the type 2 diabete.
    Orforglipron
  • HY-P0054
    GLP-1(7-36), amide acetate
    99.36%
    GLP-1(7-36), amide acetate is a major intestinal hormone that stimulates glucose-induced insulin secretion from β cells.
    GLP-1(7-36), amide acetate
  • HY-125824
    Danuglipron
    Agonist 98.63%
    Danuglipron (PF-06882961) is an orally active glucagon-like peptide-1 receptor (GLP-1R) agonist. Danuglipron has the potential for type 2 diabetes research.
    Danuglipron
  • HY-114118A
    Semaglutide TFA
    Agonist 99.92%
    Semaglutide TFA, a long-acting GLP-1 analogue, is a glucagon-like peptide-1 (GLP-1) receptor agonist. Semaglutide TFA has the potential for type 2 diabetes treatment.
    Semaglutide TFA
  • HY-50663
    MK 0893
    Antagonist 99.86%
    MK 0893 is a potent and selective glucagon receptor antagonist with an IC50 of 6.6 nM.
    MK 0893
  • HY-103546
    BETP
    Agonist 99.35%
    BETP is an agonist of glucagon-like peptide-1 (GLP-1) receptor, with EC50s of 0.66 and 0.755 μM for human and rat GLP-1 receptor, respectively.
    BETP
  • HY-121835
    GLP-1R agonist 2
    Agonist 99.94%
    GLP-1R agonist 2 (compound 2) is an effective GLP-1R agonist that exerts its activating effect by forming hydrogen bonds with the Tyr42, Cys71, and Ser84 residues of GLP-1R. GLP-1R agonist 2 has the potential for research in metabolic diseases such as type 2 diabetes and obesity.
    GLP-1R agonist 2
  • HY-P4146
    Survodutide
    Agonist 99.83%
    Survodutide (BI 456906) is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC50s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake.
    Survodutide
  • HY-101116
    GLP-1R Antagonist 1
    Antagonist 99.84%
    GLP-1R Antagonist 1 (compound 5d) is an orally active, CNS penetrant and non-competitive antagonist of glucagon-like peptide 1 receptor (GLP-1R), with an IC50 of 650 nM.
    GLP-1R Antagonist 1
  • HY-P0055A
    GLP-1(7-37) acetate
    99.63%
    GLP-1(7-37) acetate is an intestinal insulinotropic hormone that augments glucose induced insulin secretion.
    GLP-1(7-37) acetate
  • HY-19904
    Adomeglivant
    Antagonist 99.63%
    Adomeglivant (LY2409021) is a potent, selective glucagon receptor (GluR) allosteric antagonist. Adomeglivant is widely used in the research for type 2 diabetes mellitus.
    Adomeglivant
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity